Company Overview - Editas Medicine (EDIT) shares have increased by approximately 40% over the past month, outperforming the S&P 500 [1] - The most recent earnings report is crucial for understanding the catalysts affecting the stock [1] Earnings Estimates - Estimates for Editas have trended downward in the past month, with the magnitude of these revisions being net zero [2][4] - Editas currently holds a Zacks Rank 3 (Hold), indicating expectations for an in-line return in the upcoming months [4] VGM Scores - Editas has an average Growth Score of C, a Momentum Score of A, and a Value Score of F, placing it in the bottom 20% for the value investment strategy [3] - The aggregate VGM Score for Editas is D, which is relevant for investors not focused on a single strategy [3] Industry Performance - Editas is part of the Zacks Medical - Biomedical and Genetics industry, where Mirum Pharmaceuticals, Inc. (MIRM) has seen an 8.2% gain over the past month [5] - Mirum Pharmaceuticals reported revenues of $111.58 million for the last quarter, reflecting a year-over-year increase of 61.2% [6] - Mirum's expected loss for the current quarter is $0.32 per share, which is a year-over-year improvement of 38.5% [6] - Mirum Pharmaceuticals also holds a Zacks Rank 3 (Hold) and has a VGM Score of B [7]

Company Performance - CRISPR Therapeutics AG's stock closed at $42.94, reflecting a +2.02% increase from the previous day, outperforming the S&P 500's gain of 0.55% [1] - Over the past month, the company's shares have appreciated by 11.97%, significantly exceeding the Medical sector's gain of 3.49% and the S&P 500's gain of 6.29% [1] Upcoming Earnings Disclosure - The company is projected to report earnings of -$1.54 per share, indicating a year-over-year decline of 3.36% [2] - Revenue is expected to be $5.89 million, representing a substantial increase of 1032.88% compared to the same quarter last year [2] Annual Forecast - For the entire year, the Zacks Consensus Estimates predict earnings of -$5.54 per share and revenue of $39.95 million, reflecting changes of -27.65% and +7.06% respectively from the previous year [3] Analyst Estimates and Market Sentiment - Recent modifications to analyst estimates for CRISPR Therapeutics AG are crucial as they reflect short-term business trends [4] - Positive estimate revisions are viewed as a sign of optimism regarding the company's business outlook [4] Zacks Rank and Industry Performance - The Zacks Rank system, which evaluates estimate changes, currently ranks CRISPR Therapeutics AG as 3 (Hold) [6] - The Medical - Biomedical and Genetics industry, to which the company belongs, has a Zacks Industry Rank of 76, placing it in the top 31% of over 250 industries [7]

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

Company Performance - Bristol Myers Squibb (BMY) closed at $49, reflecting a +1.22% increase from the previous day, outperforming the S&P 500's daily gain of 0.09% [1] - The stock has risen by 4.22% over the past month, compared to a 2.17% gain in the Medical sector and a 7.21% gain in the S&P 500 [1] Upcoming Financial Results - The company is expected to report an EPS of $1.67, indicating a 19.32% decline year-over-year [2] - Projected revenue for the upcoming quarter is $11.32 billion, reflecting a 7.19% decrease compared to the same quarter last year [2] Annual Estimates - For the annual period, earnings are anticipated to be $6.85 per share, representing a +495.65% change from the previous year, while revenue is projected at $46.31 billion, indicating a -4.11% change [3] Analyst Forecasts - Recent revisions to analyst forecasts for Bristol Myers Squibb should be monitored, as they often reflect changes in short-term business dynamics [4] - Positive estimate revisions are seen as a sign of optimism regarding the company's business outlook [4] Zacks Rank and Valuation - The Zacks Rank system currently rates Bristol Myers Squibb at 3 (Hold), with a recent 0.57% decline in the Zacks Consensus EPS estimate [6] - The company is trading at a Forward P/E ratio of 7.06, significantly lower than the industry average of 19.71, suggesting it is trading at a discount [7] PEG Ratio and Industry Ranking - Bristol Myers Squibb has a PEG ratio of 1.41, close to the industry average of 1.43 [8] - The Medical - Biomedical and Genetics industry, which includes Bristol Myers Squibb, has a Zacks Industry Rank of 78, placing it in the top 32% of over 250 industries [8][9]

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even though momentum is a popular stock char ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD) . Shares have added about 26.1% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Acadia due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been Moving Since Th ...

Core Viewpoint - Denali Therapeutics Inc. has seen a slight increase in share price of about 0.7% over the past month, underperforming the S&P 500, raising questions about the sustainability of this trend leading up to the next earnings release [1] Group 1: Earnings and Estimates - Estimates for Denali Therapeutics have trended upward over the past month, indicating positive revisions [2] - The stock has a Zacks Rank of 3 (Hold), suggesting an expectation of in-line returns in the coming months [4] Group 2: VGM Scores - Denali Therapeutics has a poor Growth Score of F, a Momentum Score of C, and a Value Score of F, resulting in an overall aggregate VGM Score of F, placing it in the lowest quintile for investment strategies [3] Group 3: Industry Comparison - Denali Therapeutics operates within the Zacks Medical - Biomedical and Genetics industry, where Moderna has experienced a gain of 13.3% over the past month [5] - Moderna reported revenues of $108 million for the last quarter, reflecting a year-over-year decline of 35.3%, with an EPS of -$2.52 compared to -$3.07 a year ago [5] - Moderna is projected to post a loss of $2.97 per share for the current quarter, with a year-over-year change of +10.8% and a Zacks Rank of 3 (Hold) [6]

Company Overview - Jazz Pharmaceuticals (JAZZ) shares have increased by approximately 7.9% over the past month, outperforming the S&P 500 [1] - The most recent earnings report is crucial for understanding the catalysts affecting the stock [1] Earnings Estimates - Estimates for Jazz Pharmaceuticals have trended downward, with a consensus estimate shift of -213.47% over the past month [2] - The overall trend indicates a negative outlook for the stock's performance [4] VGM Scores - Jazz Pharmaceuticals has a Growth Score of B, but a low Momentum Score of F, while maintaining a Value Score of B, placing it in the top 40% for value investment strategy [3] - The aggregate VGM Score for the stock is B, which is significant for investors not focused on a single strategy [3] Industry Performance - Jazz operates within the Zacks Medical - Biomedical and Genetics industry, where another player, Alkermes (ALKS), has seen a 3.8% gain over the past month [5] - Alkermes reported revenues of $306.51 million for the last quarter, reflecting a year-over-year decline of -12.5% [5] - Alkermes is expected to post earnings of $0.43 per share for the current quarter, indicating a year-over-year change of -40.3% [6]

A month has gone by since the last earnings report for Ultragenyx (RARE) . Shares have added about 9.6% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Ultragenyx due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been Moving Since Then?It turns out ...